FDA declines to approve AbbVie's Botox follow-up
AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
FDA clears first genetic hearing loss gene therapy
Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
Trump's DOJ reschedules medicinal marijuana, increasing acce...
The US Justice Department has issued an order moving medical marijuana to Schedule III, removing some barriers to access for patients and researchers.
Ray's upscaled Series B, and other biofinancings
This week's crop of private financings includes nine-figure rounds for Ray Therapeutics and Tortugas, with Serif and Alloy also in on the action.
Novo says oral semaglutide works in diabetic kids
Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey